MedPath

Effectiveness of eye movement desensitization and reprocesssing (EMDR) therapy in rheumatoid arthritis (RA) patients with persistent pain despite inflammation being under control: a multiple baseline single case experimental design study across ten cases

Conditions
chronic pain
persistent pain
Rheumatoid Arthritis
10003816
10023213
Registration Number
NL-OMON56683
Lead Sponsor
Medisch Spectrum Twente
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
10
Inclusion Criteria

Clinical diagnosis RA
NRS pain >= 6 at screening and NRS-pain >=4 at the time of inclusion
Stable low disease activity (DAS28 < 3.2) and/or the rheumatologist's clinical
impression of low disease activity

Exclusion Criteria

An acute condition of psychosis or bipolar disorder
An acute suicidal risk
Substance dependency
Not stable on the use of medication.
Visual or hearing problems interfering with the EMDR procedure
Involved in other psychological/psychiatric treatment

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Primary endpoint for effectiveness is the pre-treatment phase A1 to<br /><br>post-treatment phase A2 difference in NRS pain intensity. Feasibility is<br /><br>examined by monitoring recruitment, dropout rates, and treatment satisfaction.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Secondary parameters are:<br /><br>* Additional physical symptoms (stiffness in muscles and joints and fatigue)<br /><br>(DQ-PiRA)<br /><br>* The impact of RA on daily life and sleep (DQ-PiRA)<br /><br>* Four PTSD symptoms will be measured with the 4itemPCL-5<br /><br>* The score on the Generalized Pain Questionnaire (GPQ)<br /><br>* The score on the Pain Disability Index (PDI)<br /><br>* The score on the Rheumatoid Arthritis Pain Scale (RAPS)<br /><br>* The total score on Beck*s depression index (BDI)</p><br>
© Copyright 2025. All Rights Reserved by MedPath